Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Nature Genetics2012Vol. 44(8), pp. 852–860
Citations Over TimeTop 1% of 2012 papers
Zhenfeng Zhang, Jae Cheol Lee, Luping Lin, Victor Olivas, Valerie Au, Thomas LaFramboise, Mohamed Abdel-Rahman, Xiaoqi Wang, Alan D. Levine, Jin Kyung Rho, Yun Jung Choi, Chang‐Min Choi, Sang-We Kim, Se Jin Jang, Young Soo Park, Woo Sung Kim, Dae Ho Lee, Jung‐Shin Lee, Vincent A. Miller, Maria E. Arcila, Marc Ladanyi, Philicia Moonsamy, Charles L. Sawyers, Titus J. Boggon, C. Patrick, Carlota Costa, Miquel Tarón, Rafael Rosell, Balázs Halmos, Trever G. Bivona
Related Papers
- → Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours(2008)84 cited
- → Gas6 and the Receptor Tyrosine Kinase Axl in Clear Cell Renal Cell Carcinoma(2009)47 cited
- → EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib(2011)21 cited
- → Engineered AXL‑ECD‑Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration(2019)9 cited
- → AXL receptor tyrosine kinase (AXL; UFO); growth arrest–specific 6 (GAS6)(2014)